Omentin-1 vs Leu-enkephalin
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and Leu-enkephalin (Tyr-Gly-Gly-Phe-Leu) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Omentin-1 | Leu-enkephalin |
|---|---|---|
| Category | Diabetes & Metabolic | Pain Management |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Tyr-Gly-Gly-Phe-Leu |
| Molecular Weight | ~35 kDa | 555.63 Da |
| Half-Life | hours | 1-5 minutes in plasma |
| Amino Acids | 313 | 5 |
| Typical Dose | No approved human dose; research use only | 0.1-5 ug per animal |
| Route | IV|SC | Intrathecal / intracerebroventricular |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 1000 |
| Research Status | Pre-clinical | Pre-clinical |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Leu-enkephalin Benefits
- ✓delta-opioid activity
- ✓endogenous analgesic model
- ✓receptor-selective pharmacology
- ✓nociception pathway research
Omentin-1 Dosing
not established|not established
Leu-enkephalin Dosing
Intrathecal 0.1-5 ug per animal|Intracerebroventricular 0.1-2 ug per animal|In vitro 1-100 nM
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Leu-enkephalin Side Effects
- ⚠sedation
- ⚠constipation-like opioid effects
- ⚠very short plasma stability
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Leu-enkephalin
Leu-enkephalin is a standard tool in opioid receptor and pain-transmission research because it helps distinguish delta- from mu-preferring signaling. Its research value is high, but its clinical utility is limited by rapid enzymatic breakdown and delivery challenges.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.